ArticleScientific reports2026
Characteristics and immune dynamics of peripheral blood immune cells and cytokines in individuals with chronic hepatitis B virus infection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatitis B virus (HBV)-related immune injury-mediated local liver inflammation and hepatocyte death are critical for the progression of chronic hepatitis B (CHB). This cross-sectional study aimed to characterize the systematic variations of peripheral blood immune cells and the corresponding changes of cytokines/chemokines during CHB progression, without implying causal relationships. Peripheral blood immune cell subsets were detected by multiparametric flow cytometry, and the levels of cytokines/chemokines were measured using the Luminex discovery assay. The study included CHB patients at different stages and healthy controls (HC), with data compared between groups, A multivariate analysis of variance (ANOVA) was used to adjust for potential confounding factors including age and gender. Compared with HC, initial CHB patients had a significantly higher frequency of total B cells (p < 0.001) but a lower proportion of CD4 + T cells (p < 0.01). The level of C-X-C chemokine ligand 10 (CXCL10) was markedly elevated in CHB patients (p < 0.01) and positively correlated with B cell frequency. Notably, CHB patients with serum Hepatitis B Surface Antigen (HBsAg) < 1500 ng/mL had higher CXCL10 levels than those with HBsAg ≥ 1500 ng/mL (p < 0.05). In late-stage HBV infection (HBV-LC and HBV-HCC), the frequency of NK cells was significantly lower than that in CHB patients and healthy controls, while the frequency of T cells showed a relative increase. Additionally, compared with CHB patients and HC, late-stage patients showed significantly higher levels of key cytokines/chemokines, including interferon-gamma (IFN-γ), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-C chemokine ligand 2 (CCL2), and tumor necrosis factor receptor I (TNFRI). This cross-sectional study reveals distinct alterations in peripheral blood immune cells and cytokines/chemokines across CHB progression, with CXCL10, NK cells, and multiple proinflammatory factors closely associated with disease stage and HBsAg levels. These findings may provide potential biomarkers for monitoring CHB progression and theoretical support for immune-based therapeutic strategies, but causal relationships require verification by subsequent longitudinal studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.